Treatment Trends and Key Data Emerging in Myelodysplastic Syndrome After ASH 2024

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, highlight treatment trends and key data emerging in the field of myelodysplastic syndromes.

EP. 1: Dissecting the Current Treatment Landscape in MDS

December 18th 2024

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.

EP. 2: The Importance of Treating Anemia in MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the importance of treating anemia in myelodysplastic syndrome.

EP. 3: Optimal Goals for Anemia and Transfusion Independence in MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, on treatment goals for anemia and transfusion independence in MDS.

EP. 4: Clinical Implications of FDA Approval of Luspatercept for Anemia in ESA-Naive Lower-Risk MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, on the FDA approval of luspatercept in ESA-naive lower-risk MDS.

EP. 5: Long-Term Transfusion Independence Data for Luspatercept vs ESAs in Lower-Risk MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss long-term transfusion independence data for luspatercept in MDS.

EP. 6: Other Potential Roles for Luspatercept in MDS And Beyond

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss other potential roles for luspatercept in MDS and beyond.

EP. 7: Where Imetelstat Fits Into the Paradigm for Transfusion-Dependent Anemia in MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the implications of the FDA approval of imetelstat for transfusion-dependent anemia in MDS.

EP. 8: The Potential of Oral HMAs in MDS

February 3rd 2025

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the potential for the use of oral HMAs in MDS.